Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at ...
There was a glimmer of hope when FDA veteran Richard Pazdur was tapped as CDER director after initially refusing the role but ...
During the pharma earnings season, which begins on Tuesday, Novo Nordisk will report the first revenue numbers from an oral ...
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 ...
Kailera Therapeutics is advancing a pipeline of obesity drugs, led by the GLP-1/GIP dual agonist ribupatide, which the ...
The draft guidance supports the agency’s new pathway designed to speed up the development of custom gene therapies.
In this bonus episode, BioSpace’s Vice President of Marketing Chantal Dresner and Careers Editor Angela Gabriel take a ...
Some 30% of clinical trials that are mandated to report their findings have not posted results to clinicaltrials.gov, the ...
By closing the Universal Cells Seattle location, Astellas is reportedly consolidating cell therapy, gene therapy and oncology ...
The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis ...
With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is “off to a ...
Business leaders must understand what patient-centric care really requires. Too often, patients, researchers and investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results